GlaxoSmithKline Stock Rating Reaffirmed by Deutsche Bank (GSK)
GlaxoSmithKline (LON:GSK)‘s stock had its “hold” rating restated by equities researchers at Deutsche Bank in a research report issued on Friday, Stock Ratings Network.com reports. They currently have a GBX 1,700 ($27.91) price objective on the stock. Deutsche Bank’s price objective points to a potential upside of 4.65% from the stock’s previous close.
GlaxoSmithKline (LON:GSK) traded down 1.69% on Friday, hitting GBX 1624.5001. The stock had a trading volume of 8,571,633 shares. GlaxoSmithKline has a 1-year low of GBX 1405.00 and a 1-year high of GBX 1816.00. The stock’s 50-day moving average is GBX 1601. and its 200-day moving average is GBX 1628.. The company’s market cap is £78.252 billion.
GSK has been the subject of a number of other recent research reports. Analysts at Cowen and Company downgraded shares of GlaxoSmithKline to a “market perform” rating in a research note to investors on Wednesday. Separately, analysts at Panmure Gordon reiterated a “hold” rating on shares of GlaxoSmithKline in a research note to investors on Wednesday. They now have a GBX 1,750 ($28.73) price target on the stock. Finally, analysts at Credit Suisse reiterated an “underperform” rating on shares of GlaxoSmithKline in a research note to investors on Thursday, January 16th. They now have a GBX 1,500 ($24.62) price target on the stock. Five investment analysts have rated the stock with a sell rating, ten have given a hold rating and eight have issued a buy rating to the company’s stock. GlaxoSmithKline has an average rating of “Hold” and a consensus target price of GBX 1,705.31 ($27.99).
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.